Patents by Inventor Guoying Zhou
Guoying Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240024392Abstract: Disclosed herein is an oncolytic HSV-1 virus genetically engineered for treatment of brain tumors, which lacks both copies of gamma 34.5 gene and an internal inverted repeat region and is optionally incorporated with immunostimulatory and/or immunotherapeutic genes. The oncolytic HSV-1 virus exhibited superior anti-tumor activity specifically in brain tumors. A pharmaceutical composition comprising the oncolytic HSV-1 virus and a pharmaceutically acceptable carrier, and a method of treatment of a brain tumor using the same is also disclosed.Type: ApplicationFiled: December 3, 2021Publication date: January 25, 2024Inventors: Xiaoqing CHEN, Yuanyuan LIU, Grace Guoying ZHOU
-
Publication number: 20230398144Abstract: Disclosed is an engineered exosome comprising a miRNA targeting human epidermal growth factor receptor 2 (HER2) synthesis and a ligand displayed on a membrane of the exosome for specific binding to a HER2 protein expressed on a cancer cell.Type: ApplicationFiled: October 25, 2021Publication date: December 14, 2023Inventors: Xiaoqing CHEN, Lei WANG, Xusha ZHOU, Grace Guoying ZHOU
-
Patent number: 11701338Abstract: The present invention relates to use of gTso thal in manufacturing a medicament for the promotion of MS-275 to cross the blood-brain barrier (BBB), and belongs to the technical field of pharmaceutical preparation. Administration of the medicament manufactured by the use of the present invention in combination with MS-275 significantly increases MS-275 to cross the BBB into the brain tissue, and prominently promotes the accumulation of MS-275 therein.Type: GrantFiled: August 7, 2020Date of Patent: July 18, 2023Assignee: Northwest Institute of Plateau Biology, Chinese Academy of SciencesInventors: Xiaohui Zhao, Ting Zhang, Huilan Yue, Jihong Tao, Wenjing Jia, Guoying Zhou, Lixin Wei, Chen Chen
-
Publication number: 20220347243Abstract: Provided is a composition for treating tumors in a subject comprising a therapeutically effective amount of an exosome carrying CTLA4-targeting miRNA and a therapeutically effective amount of an oncolytic herpes simplex virus expressing an immunostimulatory agent or both an immunostimulatory agent and an anti-PD-1 antibody. Wherein an exo-motif operably links to the seed sequence of the CTLA4-targeting miRNA to enhance the packaging of the CTLA4-targeting miRNA into the exosome.Type: ApplicationFiled: July 4, 2019Publication date: November 3, 2022Inventors: Xiaoqing Chen, Xusha Zhou, Bernard Roizman, Grace Guoying Zhou
-
Patent number: 11439679Abstract: An obligate oHSV vector comprising modified viral DNA genome is provided. A recombinant oHSV-1 construct comprising the obligate oHSV vector and a heterologous nucleic acid sequence encoding an immunostimulatory and/or immunotherapeutic agent is also provided. Compositions comprising the recombinant oHSV-1 construct can be used for treating cancers.Type: GrantFiled: September 14, 2020Date of Patent: September 13, 2022Assignee: IMMVIRA CO., LIMITEDInventors: Grace Guoying Zhou, Xiaoqing Chen, Xianjie Liu
-
Publication number: 20210290588Abstract: The present invention relates to use of gTso thal in manufacturing a medicament for the promotion of MS-275 to cross the blood-brain barrier (BBB), and belongs to the technical field of pharmaceutical preparation. Administration of the medicament manufactured by the use of the present invention in combination with MS-275 significantly increases MS-275 to cross the BBB into the brain tissue, and prominently promotes the accumulation of the medicament therein.Type: ApplicationFiled: August 7, 2020Publication date: September 23, 2021Inventors: Xiaohui ZHAO, Ting ZHANG, Huilan YUE, Jihong TAO, Wenjing JIA, Guoying ZHOU, Lixin WEI, Chen CHEN
-
Publication number: 20200405792Abstract: An obligate oHSV vector comprising modified viral DNA genome is provided. A recombinant oHSV-1 construct comprising the obligate oHSV vector and a heterologous nucleic acid sequence encoding an immunostimulatory and/or immunotherapeutic agent is also provided. Compositions comprising the recombinant oHSV-1 construct can be used for treating cancers.Type: ApplicationFiled: September 14, 2020Publication date: December 31, 2020Inventors: Grace Guoying Zhou, Xiaoqing Chen, Xianjie Liu
-
Patent number: 10821140Abstract: An obligate oHSV vector comprising modified viral DNA genome is provided. A recombinant oHSV-1 construct comprising the obligate oHSV vector and a heterologous nucleic acid sequence encoding an immunostimulatory and/or immunotherapeutic agent is also provided. Compositions comprising the recombinant oHSV-1 construct can be used for treating cancers.Type: GrantFiled: April 22, 2016Date of Patent: November 3, 2020Assignee: IMMVIRA CO., LIMITEDInventors: Grace Guoying Zhou, Xiaoqing Chen, Xianjie Liu
-
Patent number: 9803006Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles, particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.Type: GrantFiled: January 5, 2015Date of Patent: October 31, 2017Assignee: THE UNIVERSITY OF CHICAGOInventors: Guoying Zhou, Bernard Roizman
-
Patent number: 9669036Abstract: The disclosure relates to methods of controlling the state of a virus (lytic or lysogenic) in an individual, such as a method of reactivating a latent virus in an individual, comprising administering one or more agents that modulates the activity of signal transducer and activator of transcription 3 (STAT3) or any of p300, CBP or p300/CBP. Also contemplated are methods further comprising administering an HDAC modulating agent, such as an HDAC inhibiting agent or an HDAC activating agent.Type: GrantFiled: May 14, 2014Date of Patent: June 6, 2017Assignee: THE UNIVERSITY OF CHICAGOInventors: Bernard Roizman, Guoying Zhou, Te Du
-
Publication number: 20160175370Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles, particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.Type: ApplicationFiled: January 5, 2015Publication date: June 23, 2016Inventors: Guoying Zhou, Bernard Roizman
-
Publication number: 20160089376Abstract: The disclosure relates to methods of controlling the state of a virus (lytic or lysogenic) in an individual, such as a method of reactivating a latent virus in an individual, comprising administering one or more agents that modulates the activity of signal transducer and activator of transcription 3 (STAT3) or any of p300, CBP or p300/CBP. Also contemplated are methods further comprising administering an HDAC modulating agent, such as an HDAC inhibiting agent or an HDAC activating agent.Type: ApplicationFiled: May 14, 2014Publication date: March 31, 2016Inventors: Bernard Roizman, Guoying Zhou, Te Du
-
Patent number: 8927251Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells render the HSV particles. particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.Type: GrantFiled: August 30, 2006Date of Patent: January 6, 2015Assignee: The University of ChicagoInventors: Guoying Zhou, Bernard Roizman
-
Patent number: 7550148Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.Type: GrantFiled: August 30, 2005Date of Patent: June 23, 2009Assignee: The University of ChicagoInventors: Guoying Zhou, Bernard Roizman
-
Publication number: 20090136452Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells render the HSV particles. particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.Type: ApplicationFiled: August 30, 2006Publication date: May 28, 2009Applicant: THE UNIVERSITY OF CHICAGOInventors: Guoying Zhou, Bernard Roizman
-
Publication number: 20070243170Abstract: The invention relates to engineered herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.Type: ApplicationFiled: February 20, 2007Publication date: October 18, 2007Applicant: THE UNIVERSITY OF CHICAGOInventors: Bernard Roizman, Guoying Zhou
-
Publication number: 20070190027Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.Type: ApplicationFiled: August 30, 2005Publication date: August 16, 2007Inventors: Guoying Zhou, Bernard Roizman